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Background
MedImmune is the biologics business unit of AstraZeneca
with a mission of helping patients with significant unmet
medical need by developing innovative medicines. MedIm-
mune has a rich pipeline across five therapeutic areas
including oncology, respiratory, inflammatory and autoim-
munity, infectious diseases, neurosciences, cardiovascular
and gastrointestinal diseases. To realize our vision of per-
sonalized healthcare—treating the right patient with the
right drug at the right dose, we are applying cutting edge
tools such as next-gen sequencing, circulating tumor cells
and advanced PK/PD modelling across the pipeline.
Materials and methods
Fundamental to our goal of developing personalized
healthcare is gaining deep understanding of diseases across
different populations and specifically in Asians. To this
end, we have formed partnerships with Chinese academic
institutions, government agencies and industry partners,
and have a history of working with scientists/physicians in
China to develop medications that target the Asian/
Chinese patient population. For example, the AstraZeneca
product IRESSA (gefitinib), is already frontline therapy in
China for the treatment of patients with locally advanced
or metastatic non-small cell lung cancer with an activating
mutation in the EGFR gene.
Results
Most recently we set up an exciting collaboration with the
Shanghai Chest and Renji Hospitals to develop a richly
annotated database of lung cancer and hepatocellular can-
cer patient samples to aid in identifying novel drug targets
and developing therapeutic strategies to aid patients. This
presentation will provide examples in our pipeline that
give us reasons to believe in such approaches, e.g. a type I
interferon gene signature for an anti-IFN-alpha or anti-
IFNAR monoclonal antibody in patients with systemic
lupus erythematosus.
Conclusions
MedImmune is committed to helping Chinese patients
with significant unmet medical need and we believe colla-
borations with leading Chinese PIs and innovation are key
to our mission.
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